Cross-sectional study of treatment approaches of luminal HER2negative metastatic breast cancer in real practice in Moscow

Introduction: The systemic therapy of patients with metastatic luminal HER2‑negative breast cancer (mBC) in‑ cludes various options, which can be fundamentally divided into endocrine therapy and chemotherapy. According to the Clinical Guidelines, both international and Russian, the “gold standard” of the 1st line therapy for patients with metastatic luminal HER2‑negative breast cancer (mBC) is a combination of cyclindependent kinase inhib‑ itors 4 / 6 (iCDK4 / 6) with endocrine therapy (ET). However, until recently we did not have complete data on the characteristics of the Russian population of patients with luminal HER2‑breast cancer, their treatment options, and the results of this therapy.

Aim: To analyze the patients’ profile and current treatment approaches for patients with luminal HER2 mBC in routine clinical practice in Moscow.

Materials and methods: The study was performed as an observational, crosssectional and retrospective study. The data of 2,500 patients from medical institutions in Moscow who received systemic therapy for luminal HER2 mBC in AugustOctober 2021 were analyzed.

Results: The largest number of patients received iCDK4 / 6 + ET in the first and second lines: 69.0 % and 52.0 %, respectively. In the first line, 54.6 % of patients received ribociclib, 43.1 % palbociclib and 2.3 % abemaciclib. In the second line, 50.6 % of patients received ribociclib, 47.8 % palbociclib and 1.6 % abemaciclib. As the pretreatment of patients increased, preference was given to other treatment methods, therefore the proportion of combined ET decreased to 34.0 % in the third line and 25.0 % in the fourth and subsequent lines.

Conclusion: The data obtained indicate that the appointment of iCDK4 / 6 + ET is made in accordance with the Clinical Guidelines for the treatment of breast cancer of the Ministry of Health of the Russian Federation from 2021 and the preferred firstline treatment option for patients with luminal HER2 mBC in Moscow is combined endocrine therapy.

1. Malignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021.252 p (In Russ.)

2. Thangavel C., Dean J., Ertel A., et al. Therapeutically activating RB: Reestablishing cell cycle control in endocrine therapyresistant breast cancer. Endocr Relat Cancer 2011;18(3):333–345. https://doi.org/10.1530/ERC-10-0262

3. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics. CA Cancer J Clin 2017;67(1):7–30. https://doi.org/10.3322/caac.21387

4. Pernas S., Villagrasa P., Vivancos A., et al. Patientreported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA3. Annals of Oncology. 2018;29:90

5. Hortobagyi G.N. Ribociclib for the firstline treatment of advanced hormone receptorpositive breast cancer: a re view of subgroup analyses from the MONALEESA2 trial. Breast Cancer Res 2018;20(1):123. https://doi.org/10.1186/s13058-018-1050-7

6. Lu Y.S., Im S.A., Colleoni M., et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre and perimenopausal patients with HR + /HER2 − advanced breast cancer in MONALEESA7: A phase III randomized clinical trial. Clin Cancer Res 2021;28(5):851–859. https://doi.org/10.1158/1078-0432.CCR-21-3032

7. Finn R.S., Martin M., Rugo H.S., et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375(20):1925– 1936. https://doi.org/10.1056/NEJMoa1607303

8. Braal C.L., Jongbloed E.M., Wilting S.M., et al. Inhibiting CDK4/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs 2021;81(3):317–331. https://doi.org/10.1007/s40265-020-01461-2

9. Varella L., Eziokwu A.S., Jia X., et al. Realworld clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res Treat 2019;176(2):429–434. https://doi.org/10.1007/s10549-019-05176-1

10. Brufsky A., Chen C., Mardekian J., et al. Characteristics of MBC patients receiving firstline treatments in the US realword setting in the era of CDK4/6 inhibitors. SABCS 2019.P1–19–26. https://doi.org/10.1158/1538-7445. SABCS19-P1-19-26

11. Clinical Guidelines. Breast cancer, 2021. Available at: https://cr.minzdrav.gov.ru/schema/379_4 (In Russ.)

12. Постановление Правительства Москвы №177ПП от 12 марта 2019 г. «О гарантиях дополнительного лекарственного обеспечения граждан, страдающих онкологическими заболеваниями»

13. Cottu P., Ramsey S.D., SolàMorales O., et al. The emerging role of realworld data in advanced breast cancer therapy: Recommendations for collaborative decisionmaking. Breast 2022;61:118–122. https://doi.org/10.1016/j.breast.2021.12.015

14. Brufsky A., Liu X., Li B., et al. Realworld tumor response of palbociclib plus letrozole versus letrozole for metastatic breast cancer in US clinical practice. Target Oncol 2021;16(5):601–611. https://doi.org/10.1007/s11523021008261

15. Patt D., Liu X., Li B., et al. Realworld treatment patterns and outcomes of palbociclib plus an aromatase inhibitor for metastatic breast cancer: flatiron database analysis. Clin Breast Cancer 2022;22(6):601–610. https://doi.org/10.1016/j.clbc.2022.05.002

16. Lewis K., Kurovsky S., Last M., et al. 321P Firstline treatment patterns in HR +/HER2 locally advanced or metastatic breast cancer in Europe. Annals of Oncology 2020;31(4):S371–S372

17. Rinnerthaler G., Gampenrieder S.P., Tinchon C., et al. Abstract PS12–21: Firstline treatment of hormone receptor positive metastatic breast cancer (MBC) in everyday practice: Results from the Austrian AGMT_MBC-Registry. Cancer Research 2021;81 (4_Supplement):PS12–21. https://doi.org/10.1158/1538-7445.SABCS20-PS12-21

18. Swallow E., Zhang J., Thomason D., et al. Realworld patterns of endocrine therapy for metastatic hormonerecep torpositive (HR +)/human epidermal growth factor receptor2negative (HER2) breast cancer patients in the United States: 2002–2012. Curr Med Res Opin 2014;30(8):1537–1545. https://doi.org/10.1185/03007995.2014.908829

19. Goldschmidt D., Dalal A.A., Romdhani H., et al. Current treatment patterns among postmenopausal women with HR +/HER2 metastatic breast cancer in US community oncology practices: an observational study. Adv Ther 2018;35(4):482–493. https://doi.org/10.1007/s12325-018-0676-2.